Investigating iLux Efficacy in Contact Lens Wearers With Evaporative Dry Eye Disease

Phase 4

Terminated

Conditions: Dry Eye

Interventions: Device: iLux® system

Registration Number: NCT04159935

Lead Sponsor: University of Waterloo

Brief Summary: The purpose of this clinical trial is to investigate the efficacy of a single iLux® treatment in symptomatic CL wearers who have DED (according to the TFOS DEWS II diagnostic criteria), of the evaporative dry eye disease subtype (EDE).

Detailed Description: Not available

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 28

Inclusion Criteria

Is at least 18 years of age and has full legal capacity to volunteer;
Has read and signed an information consent letter;
Is willing and able to follow instructions and maintain the appointment schedule;
Has been using the same CL type (brand, material and dimensions) for > 3 months;
Wears commercially available soft CLs on average >2 hours per day, 4-7 days per week;
Is willing to try to wear their habitual CLs on average ≥ 6 hours per day, 4-7 days per week and maintain this for the duration of their involvement in the study;
Demonstrates an acceptable lens fit of their habitual contact lenses;
Does not have contact lens discomfort due to contact lens fit, lens material or known solution compatibility issues, in the opinion of the investigator;
Has at least one month supply of their habitual contact lens products at the time of the screening visit;
Has a CLDEQ-8 score ≥ 12;
Has dry eye symptoms without CL wear (OSDI ≥ 13) and has at least one of the two following signs:
1. Non-invasive tear break-up time (NITBUT) of < 10 seconds in at least one eye;
2. Fluorescein staining: > 5 spots of corneal staining OR > 9 conjunctival spots OR lid wiper staining (≥ 2mm length, ≥ 25% width) in at least one eye;
Has a lipid layer thickness of ≤ 100 nm in both eyes;
A meibomian gland secretion score (MGS) of ≤ 15 for 15 glands of the lower lid in both eyes.

Exclusion Criteria

Is participating in any concurrent clinical or research study;
Has used any prescription systemic medications or topical treatments for MGD or dry eye for the past 30 days prior to the screening visit and not willing to stop using these for the study duration (excluding over-the-counter artificial tears, dietary supplements and ocular lubricants but includes warm compresses, eyelid massage, eyelid hygiene, manual meibomian gland expression, punctal plug insertion or punctal occlusion, intense pulsed light treatment of the face or eyelids);
Has previously received treatment with an eyelid thermal pulsation device;
Has a history of any of the following ocular (eye or eyelid) conditions or procedures in either eye within the past 90 days prior to the screening visit:
1. Ocular trauma
2. Chemical burns
3. Ocular Herpes simplex or Herpes zoster infection
4. Limbal stem cell deficiency
5. Recurrent ocular inflammation (e.g. uveitis, iritis, scleritis, episcleritis, keratitis)
Has undergone ocular surgery (e.g. intraocular, oculoplastic, corneal or refractive surgery procedure) within the past 12 months prior to the screening visit;
Has permanent make-up or tattoos on their eyelids;
Has any other known active* ocular disease and/or infection in either eye including: cicatricial lid margin disease or severe (≥ grade 3) blepharitis; moderate to severe (grade 2-4) allergic, vernal or giant papillary conjunctivitis; a hordeolum or stye; ocular surface abnormality that may compromise corneal integrity (e.g. Grade 3 corneal fluorescein staining, recurrent corneal erosion, corneal epithelial defect, map dot fingerprint dystrophy, previously treated chemical burn);
Has an eyelid abnormality that affects normal lid function (e.g. entropion, ectropion, oedema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis);
Has a systemic condition that in the opinion of the investigator may affect a study outcome variable;
Has any other condition that could compromise treatment or increase the risk of a procedure-related injury;
Is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable;
Has known sensitivity to the diagnostic pharmaceuticals to be used in the study;
Has a history of sensitivity to rapidly blinking lights or photosensitive epilepsy;
Is pregnant, lactating or planning a pregnancy (by verbal communication) at the time of enrolment;
Is aphakic;
Is a member of CORE directly involved in the study;
Has taken part in a clinical research study within the last 30 days. * For the purposes of this study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. Mild (i.e. not considered clinically relevant) lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye are not considered active ocular disease. Neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
iLux® treatment	iLux® system	The treatment group will receive iLux® treatment at Visit 1 and will be reviewed 1- and 3-months after iLux® treatment.
Delayed iLux® treatment	iLux® system	Delayed iLux® treatment provided after 1 month (i.e. 1 month of no treatment, administer treatment after 1 month). Review 1- and 3-months after iLux® treatment.

Primary Outcome Measures

Name	Time	Method
Mean Change in the Standard Patient Evaluation of Eye Dryness (SPEED) Questionnaire Score From Baseline to 1 Month	1 month	The mean change in dry eye symptoms from baseline based on the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire score was evaluated 1 month after iLux treatment. The SPEED questionnaire is a dry eye questionnaire developed to assess the frequency (0-3 scale, with higher values indicating more frequent symptoms) and severity (0-4 scale, with higher values indicating more severe symptoms) of patient symptoms. Scores range from 0-28. A higher SPEED score represents more frequent and/or more severe symptoms.

Secondary Outcome Measures

Name	Time	Method
Meibomian Gland Score at 1 Month	1 Month	To determine the meibomian gland score, secretion characteristics of 15 meibomian glands along the lower eyelid were evaluated including five glands each in the temporal, central and nasal regions of the lower eyelid. For each gland, secretion characteristics were graded as 3 (clear liquid), 2 (cloudy liquid), 1 (inspissated/ toothpaste consistency) and 0 (no secretion). The total meibomian gland score is the sum of the grades for all 15 glands with a range between 0 and 45. A higher score reflects less meibomian gland dysfunction.
Comfortable Contact Lens Wear Time at 3 Months	3 Months	Participants reported how long the contact lenses on average were comfortable (comfortable wear time).
Pre-lens Tear Break-up Time at 1 Month	1 Month	The pre-lens tear film is the layer of tears located on top of the contact lens (i.e., between the eye lid and the contact lens). The time required for a dry spot to appear on the contact lens surface after blinking is referred to as the pre-lens tear break-up time. Three measurements are taken and averaged together. A higher number represents a longer pre-lens tear break-up time.
Meibomian Gland Score at 3 Months	3 Months	To determine the meibomian gland score, secretion characteristics of 15 meibomian glands along the lower eyelid were evaluated including five glands each in the temporal, central and nasal regions of the lower eyelid. For each gland, secretion characteristics were graded as 3 (clear liquid), 2 (cloudy liquid), 1 (inspissated/ toothpaste consistency) and 0 (no secretion). The total meibomian gland score is the sum of the grades for all 15 glands with a range between 0 and 45. A higher score reflects less meibomian gland dysfunction.
Average Contact Lens Wear Time at Baseline	Baseline	Participants reported how long they wore their contact lenses on average per day (total wear time).
Meibomian Gland Score at Baseline	Baseline	To determine the meibomian gland score, secretion characteristics of 15 meibomian glands along the lower eyelid were evaluated including five glands each in the temporal, central and nasal regions of the lower eyelid. For each gland, secretion characteristics were graded as 3 (clear liquid), 2 (cloudy liquid), 1 (inspissated/ toothpaste consistency) and 0 (no secretion). The total meibomian gland score is the sum of the grades for all 15 glands with a range between 0 and 45. A higher score reflects less meibomian gland dysfunction.
Comfortable Contact Lens Wear Time at Baseline	Baseline	Participants reported how long the contact lenses on average were comfortable (comfortable wear time).
Average Contact Lens Wear Time at 3 Months	3 Months	Participants reported how long they wore their contact lenses on average per day (total wear time).
Pre-lens Tear Break-up Time at Baseline	Baseline	The pre-lens tear film is the layer of tears located on top of the contact lens (i.e., between the eye lid and the contact lens). The time required for a dry spot to appear on the contact lens surface after blinking is referred to as the pre-lens tear break-up time. Three measurements are taken and averaged together. A higher number represents a longer pre-lens tear break-up time.
Comfortable Contact Lens Wear Time at 1 Month	1 Month	Participants reported how long the contact lenses on average were comfortable (comfortable wear time).
Pre-lens Tear Break-up Time at 3 Months	3 Months	The pre-lens tear film is the layer of tears located on top of the contact lens (i.e., between the eye lid and the contact lens). The time required for a dry spot to appear on the contact lens surface after blinking is referred to as the pre-lens tear break-up time. Three measurements are taken and averaged together. A higher number represents a longer pre-lens tear break-up time.
Average Contact Lens Wear Time at 1 Month	1 Month	Participants reported how long they wore their contact lenses on average per day (total wear time).